Therapeutic blockade of HMGB1 reduces early motor deficits, but not survival in the SOD1(G93A) mouse model of amyotrophic lateral sclerosis

BACKGROUND: Amyotrophic lateral sclerosis (ALS) is a fatal and rapidly progressing neurodegenerative disease without effective treatment. The receptor for advanced glycation end products (RAGE) and the toll-like receptor (TLR) system are major components of the innate immune system, which have been...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, John D., Liu, Ning, Levin, Samantha C., Ottosson, Lars, Andersson, Ulf, Harris, Helena E., Woodruff, Trent M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6380064/
https://www.ncbi.nlm.nih.gov/pubmed/30782181
http://dx.doi.org/10.1186/s12974-019-1435-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6380064/
https://www.ncbi.nlm.nih.gov/pubmed/30782181
http://dx.doi.org/10.1186/s12974-019-1435-2

Ejemplares similares